Stock ADIL ADIAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.7 USD -5.03% Intraday chart for Adial Pharmaceuticals, Inc. +5.59% -8.60%
Apr. 22 Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder MT
Apr. 12 Top Premarket Decliners MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
AQ
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
AQ
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
AQ
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
AQ
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
AQ
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
AQ
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
AQ
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
AQ
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
AQ
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
AQ
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Adial Pharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
Alcohol Use Disorder Pipeline | Clinical Trials, Key Companies - Adial Pharmaceuticals, Arbor Pharmaceuticals, Gilead Sciences
AQ
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss 'New Aspects in Substance Use Treatment' at the Annual International Society of Addiction Medicine Conference
AQ
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
AQ
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
AQ
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
AQ
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market under Nasdaq Rules
AQ
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
AQ
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADIL Stock
  4. News Adial Pharmaceuticals, Inc.
  5. Press Releases